Comparative Pharmacology
Head-to-head clinical analysis: RAUDIXIN versus RAUWILOID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: RAUDIXIN versus RAUWILOID.
RAUDIXIN vs RAUWILOID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Raudixin (reserpine) is an indole alkaloid that depletes catecholamines (norepinephrine, dopamine) and serotonin from central and peripheral neuronal storage granules by inhibiting vesicular monoamine transporter (VMAT). This leads to prolonged sympathetic blockade and reduced blood pressure.
Rauwiloid (alseroxylon) is a rauwolfia alkaloid that depletes catecholamines and serotonin from postganglionic sympathetic nerve endings and the central nervous system by inhibiting vesicular monoamine transporter (VMAT). This leads to reduced peripheral vascular resistance and decreased sympathetic outflow, resulting in antihypertensive and antipsychotic effects.
Usual adult dose: 400–1600 mg orally per day in divided doses; maximum 2400 mg/day; for severe agitation: 50–100 mg intramuscularly every 4–6 hours.
2 mg orally twice daily, adjusted based on response; maximum 4 mg twice daily.
None Documented
None Documented
Terminal elimination half-life 50-100 hours; clinical context: once-daily dosing achieves steady state in 1-2 weeks.
Terminal elimination half-life is approximately 10–12 hours. Clinical context: Requires twice-daily dosing for sustained antihypertensive effect; steady-state achieved in 2–3 days.
Primarily renal (80-90% as unchanged drug), minor biliary/fecal (10-20%).
Primarily renal excretion of metabolites; ~60–80% of a dose is eliminated in urine as metabolites, with <1% as unchanged drug. Biliary/fecal excretion accounts for ~15%.
Category C
Category C
Antihypertensive
Antihypertensive